Also, the small Israeli biotech Oramed is developing an oral version of exenatide – the active ingredient in AstraZeneca’s Byetta, but this drug is still in mid-stage trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback